Quantitative prediction of cytochrome P450 (CYP) 2D6-mediated drug interactions (Q39730908)

14 September 2017

title

Quantitative prediction of cytochrome P450 (CYP) 2D6-mediated drug interactions (English)

1 reference

14 September 2017

Michel Tod

1

1 reference

14 September 2017

Sylvain Goutelle

2

1 reference

14 September 2017

Fannie Clavel-Grabit

3

1 reference

14 September 2017

Grégoire Nicolas

4

1 reference

14 September 2017

Bruno Charpiat

5

1 reference

14 September 2017

publication date

1 August 2011

1 reference

Clinical Pharmacokinetics

14 September 2017

published in

1 reference

14 September 2017

volume

50

1 reference

14 September 2017

issue

8

1 reference

14 September 2017

page(s)

519-530

1 reference

Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Mirtazapine and paroxetine: a drug-drug interaction study in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Co-prescription of cytochrome P450 2D6/3A4 inhibitor-substrate pairs in clinical practice. A retrospective analysis of data from Norwegian primary pharmacies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Effects of Polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on Trimipramine Pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

The effects of beta-adrenoceptor antagonists and levomepromazine on the metabolic ratio of debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Thioridazine inhibits risperidone metabolism: a clinically relevant drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Prolonged pharmacokinetic drug interaction between terbinafine and amitriptyline

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

O-demethylation of codeine to morphine inhibited by low-dose levomepromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Toward optimal treatment in women: the effect of sex on metoprolol-diphenhydramine interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Little effects of low dosage of levomepromazine on plasma risperidone levels

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Influence of quinidine on the pharmacokinetics of trimipramine and on its effect on the waking EEG of healthy volunteers. A pilot study on two subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Database analyses for the prediction of in vivo drug-drug interactions from in vitro data

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Cytochrome P450-mediated metabolism in the human gut wall

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Atomoxetine Hydrochloride: Clinical Drug-Drug Interaction Prediction and Outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11592620-000000000-00000

Minimizing polymorphic metabolism in drug discovery: evaluation of the utility of in vitro methods for predicting pharmacokinetic consequences associated with CYP2D6 metabolism

21 January 2018

1 reference

12 December 2020

Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine

1 reference

12 December 2020

The effect of sertraline on the pharmacokinetics of desipramine and imipramine

1 reference

12 December 2020

Metoprolol metabolism via cytochrome P4502D6 in ethnic populations

1 reference

12 December 2020

10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes

1 reference

12 December 2020

Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone

1 reference

12 December 2020

In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists

1 reference

12 December 2020

Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite, desmethylmianserin, in depressed Japanese patients

1 reference

12 December 2020

Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects

1 reference

12 December 2020

Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans

1 reference

12 December 2020

Pharmacogenetic determination of the effects of codeine and prediction of drug interactions

1 reference

12 December 2020

Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers

1 reference

12 December 2020

Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine

1 reference

12 December 2020

Interaction between propranolol and propafenone in healthy volunteers

1 reference

12 December 2020

Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers

1 reference

12 December 2020

Effect of amiodarone on the serum concentration/dose ratio of metoprolol in patients with cardiac arrhythmia

1 reference

12 December 2020

Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test

1 reference

12 December 2020

Single-dose pharmacokinetics of perhexiline administered orally to humans

1 reference

12 December 2020

Effect of sertraline on plasma nortriptyline levels in depressed elderly

1 reference

12 December 2020

Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications

1 reference

12 December 2020

Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers

1 reference

12 December 2020

Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir

1 reference

12 December 2020

Paroxetine shifts imipramine metabolism

1 reference

12 December 2020

Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects

1 reference

12 December 2020

Therapeutic drug monitoring: antiarrhythmic drugs

1 reference

12 December 2020

Pharmacokinetics and metabolism of codeine in humans

1 reference

12 December 2020

10.2165/11592620-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

14 September 2017

1041832036

0 references

1 reference